Observational study on immunotherapy for multiple myeloma in Norway

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness and complications of novel immunotherapies for multiple myeloma in routine clinical care across Norway. It focuses on treatments such as teclistamab, elranatamab, and cilta-cel, among others. By closing knowledge gaps and generating evidence, the study seeks to inform future clinical trials and establish consensus on monitoring adverse events and implementing mitigation strategies to enhance patient survival and quality of life.

Why it matters

Who can join: the full rules

Inclusion criteria

* Participants age ≥ 18 years
* Prior diagnosis of one of the following

  * Multiple myeloma as defined according to IMWG criteria
  * Primary plasma cell leukemia as defined according to IMWG consensus definition
  * AL-amyloidosis as defined according to IMWG criteria
* Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):

  * Teclistamab (Tecvayli)
  * Elranatamab (Elrexfio)
  * Talquetamab (Talvey)
  * Idecabtagene vicleucel (ide-cel/Abecma)
  * Ciltacabtagene autoleucel (cilta-cel/Carvykti)

Exclusion Criteria:

* None

Where it's running

• St. Olavs hospital HF
  Trondheim, Norway Recruiting
• Sørlandet Hospital - Arendal
  Arendal, Norway Not yet recruiting
• Ålesund hospital, Department of hematology
  Ålesund, Norway Not yet recruiting
• Haukeland University Hospital
  Bergen, Norway Not yet recruiting
• Bodø Hospital
  Bodø, Norway Not yet recruiting
• Bærum Hospital
  Bærum, Norway Not yet recruiting

Study contacts

• Study coordinator: Tobias S Slørdahl, MD PhD
• Email: tobias.s.slordahl@ntnu.no
• Phone: +4772825100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Hungarian National Systemic Amyloidosis Registry

  This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.

  Recruiting at 12 sites Semmelweis University · Balatonfüred and 11 other locations · NCT07689331

• Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma

  This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.

  Recruiting Jules Bordet Institute · Anderlecht, Brussels Capital and 2 other locations · NCT07674498

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Infectious complications in blood cancer patients treated with bispecific antibodies

  This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.

  Recruiting at 2 sites Infanta Leonor University Hospital · Madrid, Madrid and 1 other locations · NCT07609576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.